Synmosa Biopharma (TPE: 4114) announced that it has signed an exclusive licensing, supply, and commercialization agreement with Nxera Pharma Japan, a subsidiary of Japan’s Nxera Pharma, for the insomnia therapy Quviviq (daridorexant) — granting Synmosa exclusive rights to register, obtain and maintain regulatory approvals, and commercialize the dual orexin receptor antagonist (DORA) across Singapore, Thailand, Indonesia, Malaysia, the Philippines, Vietnam, Australia, and New Zealand.
Partnership Snapshot
| Item | Detail |
|---|---|
| Licensee | Synmosa Biopharma (TPE: 4114) |
| Licensor | Nxera Pharma Japan, subsidiary of Nxera Pharma (Japan) |
| Product | Quviviq (daridorexant) – insomnia therapy |
| Agreement Type | Exclusive licensing, supply, and commercialization agreement |
| Rights Granted | Exclusive rights to submit drug registration applications, obtain and maintain regulatory approvals, and commercialize Quviviq in the licensed territories |
| Licensed Territories | Singapore, Thailand, Indonesia, Malaysia, the Philippines, Vietnam, Australia, New Zealand (8 markets) |
| Consideration to Nxera | Upfront payment; eligibility for regulatory milestone payments, sales‑based royalties, and product supply revenue (amounts not disclosed) |
| Announcement Date | 14 Oct 2026 |
Product Profile & Mechanism of Action
- Molecule: Daridorexant, marketed as Quviviq, originally developed by Switzerland’s Idorsia Pharmaceuticals.
- Class: Dual orexin receptor antagonist (DORA) — a mechanism that treats insomnia by quieting the wake‑promotion system rather than broadly sedating the brain.
- Mechanism: Blocks the binding of wake‑promoting neuropeptides (orexins) to orexin receptors OX1R and OX2R, addressing a core driver of hyperarousal in insomnia.
- Commercial Footprint: Quviviq is currently marketed in Japan for the treatment of insomnia in adults, and has been approved in Taiwan and China.
- Regulatory Pipeline: A new drug application (NDA) is under regulatory review in South Korea, with the Synmosa partnership adding eight further Asia‑Pacific registration pathways.
Regional Expansion Map – Quviviq in Asia‑Pacific
| Market | Status |
|---|---|
| Japan | Marketed (insomnia in adults) |
| Taiwan, China | Approved |
| South Korea | NDA under regulatory review |
| Singapore, Thailand, Indonesia, Malaysia, Philippines, Vietnam, Australia, New Zealand | Licensed to Synmosa – registration applications, approvals, and commercialization to be pursued |
Market Impact & Outlook
- Strategic Territory Grab: The agreement positions Synmosa as the exclusive commercial gateway for Quviviq across eight Asia‑Pacific markets, pairing the licensee’s regional regulatory and sales infrastructure with an established insomnia franchise.
- DORA Class Momentum: As a dual orexin receptor antagonist, daridorexant belongs to the newest mechanistic class in insomnia — differentiated from conventional sedative‑hypnotics by targeting the orexin wake pathway (OX1R/OX2R).
- Multi‑Stream Economics for Nxera: The structure delivers Nxera an upfront payment plus regulatory milestones, sales‑based royalties, and product supply revenue, while retaining Nxera as the product supplier across the licensed territories.
- Emerging‑Market Insomnia Burden: Southeast Asia’s large, increasingly diagnosed insomnia population — alongside mature markets Australia and New Zealand — offers a diversified growth runway spanning both emerging and developed healthcare systems.
- Registration Execution Ahead: With the product already approved or under review in Japan, Taiwan, China, and South Korea, Synmosa can leverage an existing global clinical dossier to accelerate filings across its eight territories.
- Watch Items: Registration submissions and approvals in each licensed market, commercial launch sequencing, reimbursement access in Australia/New Zealand, and competitive dynamics among DORA‑class therapies in the region.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding the licensing partnership between Synmosa Biopharma and Nxera Pharma, including registration plans, regulatory approvals, commercialization timing, and potential milestone, royalty, and supply revenues for Quviviq (daridorexant). Actual results may differ due to risks including regulatory review outcomes in each territory, market adoption and reimbursement dynamics, competitive pressures in insomnia therapeutics, supply chain execution, and the achievement of milestone conditions. Financial terms other than the disclosed structure have not been made public.-Fineline Info & Tech
